I haven't seen this article before and thought I'd share it with you all:
The Discovery of Natilizumab, A Potent Therapeutic for Multiple Sclerosis
By L. Steinman (0ct. 2012 -Journal of Cell Biology).
Multiple sclerosis (MS) is the major inflammatory demyelinating disease of the central nervous system. There is strong evidence that an immune response in the brain is a critical component of the disease. In 1992, in a collaboration between academia and biotechnology, my colleagues and I showed that 4 integrin was the critical molecule involved in the homing of immune cells into the inflamed brain. Was it sheer luck that these results led to the development of a drug for MS?
You can read the original article here (easier to read the PDF version of Full Text): http://m.jcb.rupress.org/content/199...expansion.html
Author: https://med.stanford.edu/profiles/lawrence-steinman
It was reprinted under a different title, but with a foreword, in the JAMA, Feb. 2013:
Natilizumab. Bench to Bedside and Beyond
Natalizumab has been available as a multiple sclerosis treatment for more than 5 years in Europe and the United States. Natalizumab was granted approval by the US Food and Drug Administration in 2004, only 12 years after its molecular target was cloned. Shortly after initial approval, natalizumab use was suspended pending a safety review when several natalizumab recipients were diagnosed as having progressive multifocal leukoencephalopathy. After the safety review, natalizumab was reintroduced to the market in 2006.
Since then, more than 92,000 patients have been treated with the drug. Risk stratification algorithms and progressive multifocal leukoencephalopathy management strategies have been developed, which facilitate more personalized decision making and safer natalizumab use. This review article summarizes the evolution of natalizumab from target molecule discovery through regulatory approval, voluntary suspension, reapproval, and clinical use. The natalizumab story highlights both the opportunities and risks inherent in a novel biological therapy for a progressive neurologic disease.
You can read more here: http://archneur.jamanetwork.com/arti...icleid=1389385
The Discovery of Natilizumab, A Potent Therapeutic for Multiple Sclerosis
By L. Steinman (0ct. 2012 -Journal of Cell Biology).
Multiple sclerosis (MS) is the major inflammatory demyelinating disease of the central nervous system. There is strong evidence that an immune response in the brain is a critical component of the disease. In 1992, in a collaboration between academia and biotechnology, my colleagues and I showed that 4 integrin was the critical molecule involved in the homing of immune cells into the inflamed brain. Was it sheer luck that these results led to the development of a drug for MS?
You can read the original article here (easier to read the PDF version of Full Text): http://m.jcb.rupress.org/content/199...expansion.html
Author: https://med.stanford.edu/profiles/lawrence-steinman
It was reprinted under a different title, but with a foreword, in the JAMA, Feb. 2013:
Natilizumab. Bench to Bedside and Beyond
Natalizumab has been available as a multiple sclerosis treatment for more than 5 years in Europe and the United States. Natalizumab was granted approval by the US Food and Drug Administration in 2004, only 12 years after its molecular target was cloned. Shortly after initial approval, natalizumab use was suspended pending a safety review when several natalizumab recipients were diagnosed as having progressive multifocal leukoencephalopathy. After the safety review, natalizumab was reintroduced to the market in 2006.
Since then, more than 92,000 patients have been treated with the drug. Risk stratification algorithms and progressive multifocal leukoencephalopathy management strategies have been developed, which facilitate more personalized decision making and safer natalizumab use. This review article summarizes the evolution of natalizumab from target molecule discovery through regulatory approval, voluntary suspension, reapproval, and clinical use. The natalizumab story highlights both the opportunities and risks inherent in a novel biological therapy for a progressive neurologic disease.
You can read more here: http://archneur.jamanetwork.com/arti...icleid=1389385
